LLY

970.87

+2.45%↑

JNJ

221.5

+0.17%↑

ABBV

203.32

+1.08%↑

UNH

381.9

+0.65%↑

AZN

182.77

+0.25%↑

LLY

970.87

+2.45%↑

JNJ

221.5

+0.17%↑

ABBV

203.32

+1.08%↑

UNH

381.9

+0.65%↑

AZN

182.77

+0.25%↑

LLY

970.87

+2.45%↑

JNJ

221.5

+0.17%↑

ABBV

203.32

+1.08%↑

UNH

381.9

+0.65%↑

AZN

182.77

+0.25%↑

LLY

970.87

+2.45%↑

JNJ

221.5

+0.17%↑

ABBV

203.32

+1.08%↑

UNH

381.9

+0.65%↑

AZN

182.77

+0.25%↑

LLY

970.87

+2.45%↑

JNJ

221.5

+0.17%↑

ABBV

203.32

+1.08%↑

UNH

381.9

+0.65%↑

AZN

182.77

+0.25%↑

Accueil・Liste d'Actions・Novartis AG

Novartis AG

Ouvert

145.25 -0.47

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

145.05

Max

147.24

Chiffres clés
By Trading Economics
Revenu	747M 3.2B
Ventes	189M 14B
P/E Moyenne du Secteur	20.69 49.8
BPA	1.99
Rendement du dividende	3.23
Marge bénéficiaire	23.336
Employés	75,267
EBITDA	338M 5.4B

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+16.58% upside

Dividendes
By Dow Jones
Rendement du dividende Moyenne du Secteur	3.23% 2.25%

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-2.4B 276B
Ouverture précédente	145.72
Clôture précédente	145.25

Score Technique

By Trading Central

Confiance

Bearish Evidence

N/A / 112.63 Support & Résistance

Novartis AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 avr. 2026, 09:05 UTC

Résultats

Novartis Earnings Hit by Generic Competition -- Update

28 avr. 2026, 05:51 UTC

Résultats

Novartis Could Upgrade Future Growth Outlook

27 mars 2026, 10:24 UTC

Acquisitions, Fusions, Rachats

Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion -- Update

27 mars 2026, 06:36 UTC

Acquisitions, Fusions, Rachats

Novartis to Buy Biotech Excellergy for Up to $2 Billion

28 avr. 2026, 09:18 UTC

Market Talk

Résultats

European Pharma Stocks Slip After Novartis Books Sales, Profit Drop -- Market Talk

28 avr. 2026, 07:26 UTC

Market Talk

Résultats

Novartis's Results Are Mixed -- Market Talk

28 avr. 2026, 05:07 UTC

Résultats

Novartis: Multiple Drug Readouts in 2H Could Raise Mid- to Long-Term Growth Outlook

28 avr. 2026, 05:05 UTC

Résultats

Novartis: On Track to Deliver Full-Year Guiance

28 avr. 2026, 05:04 UTC

Résultats

Novartis Sees 2026 Core Operating Income Declining by Low Single-digit

28 avr. 2026, 05:04 UTC

Résultats

Novartis Sees 2026 Net Sales Growing by Low Single-digit

28 avr. 2026, 05:03 UTC

Résultats

Novartis 1Q Core EPS $1.99

28 avr. 2026, 05:03 UTC

Résultats

Analysts Saw Novartis 1Q Core Operating Profit at $5.1B

28 avr. 2026, 05:02 UTC

Résultats

Novartis 1Q Core Operating Profit $4.90B

28 avr. 2026, 05:02 UTC

Résultats

Analysts Saw Novartis 1Q Sales at $13.34B

28 avr. 2026, 05:01 UTC

Résultats

Novartis 1Q Sales $13.11B

28 avr. 2026, 05:00 UTC

Résultats

Novartis Backs 2026 View

28 avr. 2026, 05:00 UTC

Résultats

Novartis AG 1Q EPS $1.65

28 avr. 2026, 05:00 UTC

Résultats

Novartis AG 1Q Net Pft $3.2B

28 avr. 2026, 05:00 UTC

Résultats

Novartis AG 1Q Adj EPS $1.99

24 avr. 2026, 05:20 UTC

Résultats

Novartis Is Making Coartem Available on Largely Not-For-Profit Basis in Malaria-Endemic Regions

24 avr. 2026, 05:19 UTC

Résultats

Novartis: Process Is to Assess Quality, Safety and Efficacy of Treatments

24 avr. 2026, 05:19 UTC

Résultats

Novartis: Prequalification Is a Process Run by the WHO

10 avr. 2026, 11:45 UTC

Market Talk

Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

2 avr. 2026, 08:01 UTC

Market Talk

Novartis Likely to Confirm Guidance -- Market Talk

30 mars 2026, 09:37 UTC

Market Talk

Novartis to Take Earnings Hit From Generic Competition -- Market Talk

27 mars 2026, 07:54 UTC

Market Talk

Acquisitions, Fusions, Rachats

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

27 mars 2026, 06:22 UTC

Acquisitions, Fusions, Rachats

Correct: Novartis Will Pay Up to $2B Upfront, and Milestone Payments

27 mars 2026, 06:05 UTC

Acquisitions, Fusions, Rachats

Novartis: Transaction Is Expected to Close in 2H 2026, Subject to Approvals

27 mars 2026, 06:04 UTC

Acquisitions, Fusions, Rachats

Novartis Will Pay Up to $2B Upfront Followed by Milestone Payments

27 mars 2026, 06:03 UTC

Acquisitions, Fusions, Rachats

Novartis: Exl-111 Is a Half-Life Extended, High-Affinity anti-IgE Antibody in Phase 1

Comparaison

Variation de prix

Novartis AG prévision

Objectif de Prix

By TipRanks

16.58% hausse

Prévisions sur 12 Mois

Moyen 170.24 USD 16.58%

Haut 180.191 USD

Bas 141 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

N/A / 112.63Support & Résistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.